Navigation Links
Solta Medical Receives Regulatory Approval to Market Thermage Systems in China
Date:4/30/2009

HAYWARD, Calif., April 30 /PRNewswire-FirstCall/ -- Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced that it has received regulatory clearance to market and sell Thermage(R) systems in China. "We are excited about the opportunity to market the premier non-invasive procedure for tightening and contouring skin in the People's Republic of China," said Stephen J. Fanning, Chairman of the Board, President and CEO of Solta Medical. "We have also applied for regulatory approvals in China for our Fraxel(R) products and expect upon approval that these products will allow us to address additional opportunities in the Chinese market."

About Solta Medical, Inc.

Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective anti-aging solutions for patients which enhance and expand the practice of medical aesthetics for physicians.

The company offers products to address aging skin under the industry's two premier brands: Thermage(R) and Fraxel(R). Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Since 2002, over one million Thermage and Fraxel procedures have been performed in nearly 80 countries. Thermage and Fraxel are the perfect complement for any aesthetic practice. For more information about Solta Medical, call 877-782-2286 or log on to www.Solta.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Solta Medical's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Solta Medical's business and its financial results are detailed in its Form 10-K for the year ended December 31, 2008, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. Solta Medical undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

    CONTACT:
    Jack Glenn, Chief Financial Officer of Solta Medical, Inc.,
    +1-510-786-6890; or
    investors,
    Doug Sherk,
    or Jenifer Kirtland, jkirtland@evcgroup.com,
    both of EVC Group, +1-415-896-6820, for Solta Medical, Inc.
    Web Site:http://www.Solta.com


'/>"/>
SOURCE Solta Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Thermage, Inc. Announces Name Change to Solta Medical, Inc.
2. Video: Solta Medical Introduces Advanced Thermage Body Tip 16.0 for Faster Body Shaping and Contouring Treatments
3. Solta Medical, Inc. Announces Preliminary Financial Results for the Fourth Quarter of 2008
4. Solta Medical Reports Fourth Quarter and Full Year 2008 Results
5. Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center
6. Solta Medical, Inc. Secures $9M Credit Facility from Silicon Valley Bank
7. Solta Medical Presents Expert Roundtable about Thermage(R) and Fraxel(R) Combination Treatments at ASLMS Annual Meeting
8. Solta Medical, Inc. Announces First Quarter 2009 Results Release Date and Conference Call
9. MSU engineering team designs innovative medical device
10. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... , ... “When the Stars Lead Home”: a poignant story of loss, determination, ... Weigel Douglas, an avid reader who lives in the Pacific Northwest with her husband, ... Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year old Tizzy could not ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... recipient of proceeds from its 14th Annual Clays for Kids fundraiser, to be ... 30, Bennett, Colorado. , As part of BluSky’s partnership with The Adoption ...
(Date:5/26/2017)... ... ... “Cactus Jack: Against All Odds”: the story of Coach Cactus Jack and ... Odds” is the creation of published author, Walter Hubbard, a retired wildlife and fisheries ... child Jane. Walter. Walter and Jane have three adult children and a granddaughter. ...
(Date:5/24/2017)... BELLEVILLE, N.J. (PRWEB) , ... May 24, 2017 ... ... joined Clara Maass Medical Center CEO Mary Ellen, hospital employees, and town officials ... in Belleville. , The facility was developed by Rendina as part of its ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD ... New York City. He is known for his distinguished expertise and experience in the ... Benvenisty holds sub-specialty training in treating renovascular disease and aortic aneurysm . He ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
(Date:5/22/2017)... 2017  Lilac Corp, the company that sells ... of a new website . The website ... clinical study that showed surprising clearance of the ... individuals suffering from HPV warts, precancerous, or cancerous ... no other treatments that clear the virus. Specifically, ...
(Date:5/18/2017)... May 17, 2017  Bayer announced today that the ... be presented at the 53 rd Annual Meeting ... place June 2-6 in Chicago . ... span prostate, colorectal, liver and thyroid cancers, as well ... Phase II CHRONOS-1 trial of copanlisib in patients with ...
Breaking Medicine Technology: